O’Melveny Represents TransThera Sciences in Its H-Share IPO on The Hong Kong Exchange
June 23, 2025
FOR IMMEDIATE RELEASE
HONG KONG—June 23, 2025— O’Melveny represented TransThera Sciences (Nanjing), Inc. (“TransThera”, 2617.HK) in its listing of H shares on the Main Board of the Hong Kong Exchange. The offering size is approximately HK$200 million (approximately US$25 million). O’Melveny acted as the Hong Kong and U.S. counsel to the company, and led the drafting of the prospectus.
TransThera is a clinical demand-oriented biopharmaceutical company focusing on developing innovative small molecule therapies for oncology, inflammatory and cardiometabolic diseases. In registrational clinical stage, its core product Tinengotinib has potential to address the clinical needs in a variety of relapsed or refractory, drug-resistant solid tumors.
CLSA Limited and Huatai International acted as joint sponsors, other underwriters include BOCOM International, BOC International, CMB International, SPDB International and TradeGo Markets.
The team was led by partners Ke Geng and Ke Zhu. The core team members included counsel Stella Hu, Yazhe Liu and Qianyu Hu, associates Jingwei Huang, Fan Wu, Minhui Chen, legal manager Rachel Peng, legal consultant Daniel Tian and trainee solicitor Norman Luk.
About O’Melveny
It’s more than what you do: it’s how you do it. Across sectors and borders, in board rooms and courtrooms, we measure our success by yours. And in our interactions, we commit to making your O’Melveny experience as satisfying as the outcomes we help you achieve. Our greatest accomplishment is ensuring that you never have to choose between premier lawyering and exceptional service. So, tell us. What do you want to achieve? Visit us at www.omm.com; learn more in our firm at-a-glance; and find us on LinkedIn, Facebook, Instagram, and YouTube.
Contact:
Brandon Jacobsen
O’Melveny & Myers LLP
+1 213 430 8024
bjacobsen@omm.com
Chris Schob
O’Melveny & Myers LLP
+86 21 2307 7000
cschob@omm.com
# # #